Evidence map›Paper›PMID 38141761›Full record

ArticleThe Journal of biological chemistry2024

PP2A inhibitor SET promotes mTORC1 and Bmi1 signaling through Akt activation and maintains the colony-formation ability of cancer cells.

Naoki Kohyanagi, Nao Kitamura, Shunta Ikeda, Shusaku Shibutani, Koichi Sato, Takashi Ohama

Open access · goldAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Naoki KohyanagiLaboratory of Veterinary Pharmacology, Yamaguchi University Joint Graduate School of Veterinary Medicine, Yamaguchi, Japan.
Nao KitamuraLaboratory of Veterinary Pharmacology, Yamaguchi University Joint Graduate School of Veterinary Medicine, Yamaguchi, Japan.
Shunta IkedaLaboratory of Veterinary Pharmacology, Yamaguchi University Joint Graduate School of Veterinary Medicine, Yamaguchi, Japan.
Shusaku ShibutaniLaboratory of Veterinary Hygiene, Yamaguchi University Joint Graduate School of Veterinary Medicine, Yamaguchi, Japan.
Koichi SatoLaboratory of Veterinary Pharmacology, Yamaguchi University Joint Graduate School of Veterinary Medicine, Yamaguchi, Japan.
Takashi OhamaLaboratory of Veterinary Pharmacology, Yamaguchi University Joint Graduate School of Veterinary Medicine, Yamaguchi, Japan. Electronic address: t.ohama@yamaguchi-u.ac.jp.
Yamaguchi University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Protein phosphatase 2A (PP2A) is an essential tumor suppressor, with its activity often hindered in cancer cells by endogenous PP2A inhibitory proteins like SE translocation (SET). SET/PP2A axis plays a pivotal role in the colony-formation ability of cancer cells and the stabilization of c-Myc and E2F1 proteins implicated in this process. However, in osteosarcoma cell line HOS, SET knock-down (KD) suppresses the colony-formation ability without affecting c-Myc and E2F1. This study aimed to unravel the molecular mechanism through which SET enhances the colony-formation ability of HOS cells and determine if it is generalized to other cancer cells. Transcriptome analysis unveiled that SET KD suppressed mTORC1 signaling. SET KD inhibited Akt phosphorylation, an upstream kinase for mTORC1. PP2A inhibitor blocked SET KD-mediated decrease in phosphorylation of Akt and a mTORC1 substrate p70S6K. A constitutively active Akt restored decreased colony-formation ability by SET KD, indicating the SET/PP2A/Akt/mTORC1 axis. Additionally, enrichment analysis highlighted that Bmi-1, a polycomb group protein, is affected by SET KD. SET KD decreased Bmi-1 protein by Akt inhibition but not by mTORC1 inhibition, and exogenous Bmi-1 expression rescued the reduced colony formation by SET KD. Four out of eight cancer cell lines exhibited decreased Bmi-1 by SET KD. Further analysis of these cell lines revealed that Myc activity plays a role in SET KD-mediated Bmi-1 degradation. These findings provide new insights into the molecular mechanism of SET-regulated colony-formation ability, which involved Akt-mediated activation of mTORC1/p70S6K and Bmi-1 signaling.

Indexed as

DNA-Binding ProteinsEnzyme InhibitorsHistone ChaperonesMechanistic Target of Rapamycin Complex 1NeoplasmsPolycomb Repressive Complex 1Protein Phosphatase 2Proto-Oncogene Proteins c-aktCell Line, TumorEnzyme ActivationHumansPhosphorylationProto-Oncogene Proteins c-mycRibosomal Protein S6 Kinases, 70-kDaSignal TransductionTOR Serine-Threonine KinasesBMI1 protein, humanDNA-Binding ProteinsEnzyme InhibitorsHistone ChaperonesMechanistic Target of Rapamycin Complex 1MYC protein, humanPolycomb Repressive Complex 1Protein Phosphatase 2Proto-Oncogene Proteins c-aktProto-Oncogene Proteins c-mycRibosomal Protein S6 Kinases, 70-kDaSET protein, humanTOR Serine-Threonine KinasesAkt/PKBBmi-1cancer biologymammalian target of rapamycinpolycombprotein phosphatase 2ASET

Identifiers

PMID38141761
PMCPMC10826185
OpenAlexW4390079573

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.